Psychiatry & Neurology Doctors in Frankfort, KY Accepting Medicare

4 Psychiatry & Neurology doctors found. Showing 1 - 4

Ramesh Ghanta, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 4 Physicians Park, Frankfort, KY 40601 Phone: 270-744-9600

Carol J Miller, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 191 Doctors Dr, Frankfort, KY 40601 Phone: 859-253-1686    Fax: 859-254-2743

Dr. Scott A Haas, M.D. Psychiatry & Neurology - Forensic Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 275 E Main St, Frankfort, KY 40601 Phone: 502-296-1989    Fax: 606-668-3435

Michael J Moran, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 191 Doctors Dr, Frankfort, KY 40601 Phone: 859-253-1686

News Archive

HemoCue wins patent infringement suit

For more than two years, HemoCue AB and EKF-diagnostics GmbH, a company in Magdeburg, Germany, have been involved in a patent infringement suit.

Artificial 'cells' that boost the immune response to cancer

Using artificial cell-like particles, Yale biomedical engineers have devised a rapid and efficient way to produce a 45-fold enhancement of T cell activation and expansion, an immune response important for a patient's ability to fight cancer and infectious diseases, according to an advance on line report in Molecular Therapy.

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Squamous cell carcinoma is one of the most common cancers of the skin and mucosa. Treatment options for the advanced stage have been very limited for patients with tumors of the head and neck, i.e. in the mouth, the pharynx or the larynx: If recurrences or metastases occur during or after platinum-based chemotherapy, the disease is generally considered incurable.

Targeted therapies could treat a broad range of cancers: Research

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

Read more Medical News

› Verified 4 days ago